LEUVEN, Belgium, STRASBOURG, France, and PHILADELPHIA, March 21, 2024 – In a significant enhancement to its board, Flamingo Therapeutics, a trailblazer in RNA-targeted oncology treatments, has announced the appointment of Dr. Ezra Cohen, a distinguished medical oncologist and cancer researcher, to its Board of Directors. This strategic move amplifies the company’s commitment to advancing its pioneering oncology therapies, notably its RNA-targeting approach in cancer treatment.
Dr. Cohen’s vast experience in the field, particularly his contributions to head and neck cancer drug development, aligns seamlessly with Flamingo’s current clinical endeavors. The company is notably advancing its lead therapeutic, danvatirsen, in the PEMDA-HN Phase 2 trial for Head & Neck Cancer (HNSCC), alongside a Phase 1 study targeting Acute Myeloid Leukemia (AML) and Myelodysplastic Syndrome (MDS).
Stephane van Rooijen, MD, MBA, Chief Executive Officer of Flamingo, expressed enthusiasm about Dr. Cohen’s board membership, stating, “Ezra is a recognized leader in oncology drug development and cancer research, and we feel privileged that he will join us as we continue to advance our lead therapeutic danvatirsen in the PEMDA-HN Phase 2 trial in Head & Neck Cancer (HNSCC) and a Phase 1 investigator-initiated study in Acute Myeloid Leukemia (AML) and Myelodysplastic Syndrome (MDS).”
Currently serving as the Chief Medical Officer of Oncology for Tempus AI, Dr. Cohen brings a wealth of experience from his previous roles, including his tenure as Chief of the Division of Hematology-Oncology and Associate Director of Clinical Science at UC San Diego Moores Cancer Center. His leadership in the Precision Immunotherapy Clinic and co-direction of the San Diego Center for Precision Immunotherapy at UCSD have been pivotal in his career.
Dr. Cohen shared his excitement about joining Flamingo’s Board, highlighting the company’s innovative approach and his anticipation of contributing to groundbreaking oncology treatments. “The science and team at Flamingo are very impressive and I am excited to join the Board following the recent initiation of several important oncology clinical studies. I believe that Flamingo is uniquely positioned to improve the head and neck treatment landscape with its RNA-targeting approach, and I look forward to working with the team to deliver new therapeutic options for patients.”
Chris Mirabelli, PhD, Chairman of the Board of Flamingo, praised Dr. Cohen’s expertise and his expected impact on the board’s efforts to enhance oncology treatment options through Flamingo’s RNA-targeted therapies.
About Flamingo Therapeutics:
Comments 1